I forgot to show the interim step between the number of patients receiving each drug and the sales revenue being received by our partner in each quarter, which is then summed into annual sales revenue.
FY: 2024 2025 2026 2027 2027 2028 2029 2030 2031 2032 2033 Quarter: 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 Market Growth of Daybue Daybue patients (USA) 800 1050 1300 1550 1800 2050 2300 2550 2800 3050 3300 3550 3800 4050 4300 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 Sales revenue $m /qtr 70 91.875 113.75 135.625 157.5 179.375 201.25 223.125 245 266.875 288.75 310.625 332.5 354.375 376.25 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 393.75 Daybue patients (Rest of World) 200 600 1000 1400 1800 2200 2600 3000 3400 3800 4200 4600 5000 5400 5800 6200 6600 7000 7400 7800 8200 8600 9000 9400 9800 10200 10600 11000 11400 11800 12000 12000 12000 12000 12000 12000 Sales revenue $m /qtr 10 30 50 70 90 110 130 150 170 190 210 230 250 270 290 310 330 350 370 390 410 430 450 470 490 510 530 550 570 590 600 600 600 600 600 600 Market Growth of NNZ2591 - USA Phelan McDermid patients 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750 4000 4250 4500 4750 5000 5250 5500 5750 6000 Pitt-Hopkins patients 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750 4000 4250 4500 4750 5000 5250 Angelman patients 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750 4000 4250 4500 4750 5000 Prader-Willi patients 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750 4000 4250 4500 4750 5000 Sales Revenue of NNZ 2591 - USA per quarter Phelan McDermid patients 0 43.75 65.63 87.50 109.38 131.25 153.13 175.00 196.88 218.75 240.63 262.50 284.38 306.25 328.13 350.00 371.88 393.75 415.63 437.50 459.38 481.25 503.13 525.00 Pitt-Hopkins patients 0 0.00 0.00 0.00 43.75 65.63 87.50 109.38 131.25 153.13 175.00 196.88 218.75 240.63 262.50 284.38 306.25 328.13 350.00 371.88 393.75 415.63 437.50 459.38 Angelman patients 0 0.00 0.00 0.00 0.00 43.75 65.63 87.50 109.38 131.25 153.13 175.00 196.88 218.75 240.63 262.50 284.38 306.25 328.13 350.00 371.88 393.75 415.63 437.50 Prader-Willi patients 0 0.00 0.00 0.00 0.00 43.75 65.63 87.50 109.38 131.25 153.13 175.00 196.88 218.75 240.63 262.50 284.38 306.25 328.13 350.00 371.88 393.75 415.63 437.50 Annual Sales Revenue of NNZ 2591 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Phelan McDermid patients 196.875 568.75 918.75 1268.75 1618.75 1968.75 Pitt-Hopkins patients 0 306.25 656.25 1006.25 1356.25 1706.25 Angelman patients 0 196.875 568.75 918.75 1268.75 1618.75 Prader-Willi patients 0 196.875 568.75 918.75 1268.75 1618.75
Share Price, page-8696
-
- There are more pages in this discussion • 2,260 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.47 |
Change
0.370(1.84%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.249M | 61.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 420 | $20.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.48 | 126 | 8 |
View Market Depth
| Last trade - 12.56pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |